{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:06:45Z","timestamp":1787828805605,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007458","name":"Deutschen Multiple Sklerose Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.msard.2021.103279","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:32:47Z","timestamp":1632738767000},"page":"103279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies"],"prefix":"10.1016","volume":"56","author":[{"given":"Daniel","family":"Rapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Sch\u00f6pe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Schwingshackl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makbule","family":"Senel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103279_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.msard.2021.103279_bib0002","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.14336\/AD.2021.0106","article-title":"Systematic review of studies on Telomere length in patients with multiple sclerosis","volume":"12","author":"B\u00fchring","year":"2021","journal-title":"Aging Dis."},{"key":"10.1016\/j.msard.2021.103279_bib0003","article-title":"Non-infectious comorbidity in patients with multiple sclerosis: a national cohort study in Sweden. Multiple Sclerosis Journal - Experimental","volume":"6","author":"Castelo-Branco","year":"2020","journal-title":"Transl. Clin."},{"key":"10.1016\/j.msard.2021.103279_bib0004","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000320245","article-title":"Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study","volume":"35","author":"Christiansen","year":"2010","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2021.103279_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/14737175.2014.915742","article-title":"The current role of mitoxantrone in the treatment of multiple sclerosis","volume":"14","author":"Cocco","year":"2014","journal-title":"Expert Rev. Neurotherapeut."},{"key":"10.1016\/j.msard.2021.103279_bib0006","unstructured":"Cochrane Multiple Sclerosis and Rare Disease of the CNS, 2020. Search strategies for the identification of studies."},{"key":"10.1016\/j.msard.2021.103279_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1352458519892555","article-title":"Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment","volume":"26","author":"Cohen","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103279_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.msard.2018.08.022","article-title":"Exploring the role of physical activity and exercise for managing vascular comorbidities in people with multiple sclerosis: a scoping review","volume":"26","author":"Ewanchuk","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103279_bib0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/jcm9020335","article-title":"Cardiac autonomic dysfunction in multiple sclerosis: a systematic review of current knowledge and impact of immunotherapies","volume":"9","author":"Findling","year":"2020","journal-title":"JCM"},{"key":"10.1016\/j.msard.2021.103279_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1352458519868078","article-title":"ECTRIMS 2019 - Poster Session 1","volume":"25","author":"Frisell","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103279_bib0011","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1093\/brain\/awaa255","article-title":"Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships","volume":"143","author":"Geraldes","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103279_bib0012","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International expert consensus document on Takotsubo Syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.msard.2021.103279_bib0013","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014Imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2021.103279_bib0014","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2014Inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2021.103279_bib0015","doi-asserted-by":"crossref","first-page":"e16149","DOI":"10.1371\/journal.pone.0016149","article-title":"Smoking and multiple sclerosis: an updated meta-analysis","volume":"6","author":"Handel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2021.103279_bib0016","doi-asserted-by":"crossref","unstructured":"Higgins, J., Thomas, J., Cumpston, M., Page, M., Welch, V., n.d. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020).","DOI":"10.1002\/9781119536604"},{"key":"10.1016\/j.msard.2021.103279_bib0017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2021.103279_bib0018","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"612","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.msard.2021.103279_bib0019","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1177\/1352458513475833","article-title":"High risk of cardiovascular diseases after diagnosis of multiple sclerosis","volume":"19","author":"Jadidi","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103279_bib0020","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/WNL.0b013e3181e0f7e6","article-title":"Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS","volume":"74","author":"Kingwell","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103279_bib0021","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103279_bib0022","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp-2015-310361","article-title":"Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios","volume":"87","author":"Manouchehrinia","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2021.103279_bib0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1212\/CPJ.0000000000000230","article-title":"Differing trends in the incidence of vascular comorbidity in MS and the general population","volume":"6","author":"Marrie","year":"2016","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2021.103279_bib0024","doi-asserted-by":"crossref","first-page":"e1624","DOI":"10.1212\/WNL.0000000000007251","article-title":"Traditional risk factors may not explain increased incidence of myocardial infarction in MS","volume":"92","author":"Marrie","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103279_bib0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1352458514564485","article-title":"A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103279_bib0026","unstructured":"McGuinness, L., 2021. robvis: an R package and web application for visualising risk-of-bias assessments 2021."},{"key":"10.1016\/j.msard.2021.103279_bib0027","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIR.0000000000000351","article-title":"Acute myocardial infarction in women: a scientific statement from the American heart association","volume":"133","author":"Mehta","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.msard.2021.103279_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.msard.2021.103279_bib0029","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.envint.2018.11.004","article-title":"A risk of bias instrument for non-randomized studies of exposures: a users\u2019 guide to its application in the context of GRADE","volume":"122","author":"Morgan","year":"2019","journal-title":"Environ. Int."},{"key":"10.1016\/j.msard.2021.103279_bib0030","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.envint.2018.07.015","article-title":"Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes","volume":"121","author":"Morgan","year":"2018","journal-title":"Environ. Int."},{"key":"10.1016\/j.msard.2021.103279_bib0031","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1191\/1352458505ms1188oa","article-title":"Physical activity and multiple sclerosis: a meta-analysis","volume":"11","author":"Motl","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103279_bib0032","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaneurol.2020.0664","article-title":"Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England","volume":"77","author":"Palladino","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103279_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101423","article-title":"Incident cardiovascular disease in patients diagnosed with multiple sclerosis: a multi-database study","volume":"37","author":"Persson","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103279_bib0034","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/ene.12518","article-title":"Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study","volume":"21","author":"Roshanisefat","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103279_bib0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.msard.2021.103279_bib0036","article-title":"National estimates of self-reported sitting time in adults with multiple sclerosis","volume":"4","author":"Sasaki","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2021.103279_bib0037","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2021.103279_bib0038","article-title":"Improving the trustworthiness of findings from nutrition evidence syntheses: assessing risk of bias and rating the certainty of evidence","author":"Schwingshackl","year":"2020","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.msard.2021.103279_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2021.103279_bib0040","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiologyA proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2021.103279_bib0041","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0895-4356(02)00443-2","article-title":"Hazard rate ratio and prospective epidemiological studies","volume":"55","author":"Symons","year":"2002","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2021.103279_bib0042","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1007\/s00415-016-8295-9","article-title":"Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark","volume":"263","author":"Thormann","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103279_bib0043","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/1352458518823482","article-title":"The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations","volume":"25","author":"Valencia-Sanchez","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103279_bib0044","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2042098613481023","article-title":"Fingolimod and cardiac risk: latest findings and clinical implications","volume":"4","author":"Vargas","year":"2013","journal-title":"Therapeut. Adv. Drug Safe."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:16Z","timestamp":1761901036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821005460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":44,"alternative-id":["S2211034821005460"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103279","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103279"}}